Recent Quotes

Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. The company expects to accelerate growth of ILUVIEN through increased penetration of existing markets; expansion into new markets; and a new indication for non-infectious posterior uveitis in the EU.

Earnings

Q3 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-10-27
REV		(EXPECTED)2021-10-27

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-10
REV		(EXPECTED)2021-08-10

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
ALIM	Alimera Sciences	8.95	0.24	2.76%		60.2M

Alimera Sciences Frequently Asked Questions

How do I buy Alimera Sciences (ALIM) stock?

You can purchase shares of Alimera Sciences (NASDAQ: ALIM) through any online brokerage.

View our list of the best stock brokerages.

Who are Alimera Sciences's (ALIM) competitors?

Other companies in Alimera Sciences’s space includes: Graybug Vision (NASDAQ:GRAY), Opiant Pharmaceuticals (NASDAQ:OPNT), Teligent (NASDAQ:TLGT), Cumberland (NASDAQ:CPIX) and Baudax Bio (NASDAQ:BXRX).

What is the target price for Alimera Sciences (ALIM) stock?

The latest price target for Alimera Sciences (NASDAQ: ALIM) was reported by HC Wainwright & Co. on April 15, 2021. The analyst firm set a price target for 16.00 expecting ALIM to rise to within 12 months (a possible 83.70% upside). 1 analyst firms have reported ratings in the last year.

Current Stock Price for Alimera Sciences (ALIM)?

The stock price for Alimera Sciences (NASDAQ: ALIM) is $8.71 last updated Today at 8:00:03 PM.

Does Alimera Sciences (ALIM) pay a dividend?

There are no upcoming dividends for Alimera Sciences.

When is Alimera Sciences (NASDAQ:ALIM) reporting earnings?

Alimera Sciences’s Q3 earnings are confirmed for after-market on October 27, 2021.

Is Alimera Sciences (ALIM) going to split?

There is no upcoming split for Alimera Sciences.

What sector and industry does Alimera Sciences (ALIM) operate in?

Alimera Sciences is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.